SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg10/5/2005 5:34:26 PM
  Read Replies (1) of 1826
 
It seems as if Dean Mitchell ex-CEO of Guilford was very motivated, eager and happy to see the deal go through. He sold some 60.000 shares in MOGN, as soon as they became available to him, at prices between 23 and 23,50. He should have netted about 1,4 mUSD. Not too shabby. He was appointed to his position at Guilford (wich company was in serious trouble at the time) in December of last year. He will remain with MOGN as a Director.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News